ニューポジェン（フィルグラスチム）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

ニューポジェン（フィルグラスチム）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5％で17億2,710万米ドルに成長します。予測期間の成長は、費用対効果の高い好中球減少症治療に対する需要の高まり、新興市場におけるヘルスケアアクセスの拡大、バイオシミラー普及に対する政府支援の増加、個別化医療への注目度の向上、高齢者の増加などに起因すると考えられます。予測期間における主要動向としては、バイオシミラーへの研究開発投資の増加、好中球減少症治療用ドラッグデリバリーシステムの進歩、がん治療の商業化に向けたパートナーシップの高まり、患者負担軽減プログラムへの重点化、次世代G-CSF製剤の開発などが挙げられます。

様々な疾患の有病率の増加は、今後数年間のニューポジェン（フィルグラスチム）市場の成長を牽引すると予想されます。感染症、遺伝的要因、環境の影響、生活習慣の選択などによる疾病は、人口の高齢化、座りがちな生活、公害、食生活の乱れなどの要因により、より一般的になってきています。ニューポジェン（フィルグラスチム）は、好中球の産生を刺激することによって化学療法による好中球減少症の管理に重要な役割を果たしており、免疫力が低下した患者の感染症と闘う免疫系の能力を高めるのに役立っています。これは入院を減らし、継続的ながん治療を可能にするために不可欠です。アレルギーUKによると、2022年には英国で2,100万人以上がアレルギーに苦しんでおり、その数は増加すると予想されています。また、英国では2025年までに350万人近くががんと共に生きると予測されており、ニューポジェンのような治療に対するニーズの高まりを浮き彫りにしています。このような動向は、ニューポジェン（フィルグラスチム）の需要を今後大きく押し上げると考えられます。

ヘルスケアにおける研究開発に対する政府のイニシアチブは、ニューポジェン（フィルグラスチム）市場を促進すると予想されます。世界各国の政府は、ヘルスケア研究への資金提供やライフサイエンス製造の拡大にますます注力し、治療の可用性を向上させています。例えば、英国政府は2022年に、NHS主導の新しい診断法や治療法の研究を支援し、ライフサイエンス製造を拡大するために2億6,000万英ポンドの資金提供を発表しました。このような投資はイノベーションを促進し、先端治療へのアクセスを向上させ、ニューポージェンのような治療法の成長を直接的に支援します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のニューポジェン（フィルグラスチム）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のニューポジェン（フィルグラスチム）市場：成長率分析
• 世界のニューポジェン（フィルグラスチム）市場の実績：規模と成長、2019～2024年
• 世界のニューポジェン（フィルグラスチム）市場の予測：規模と成長、2024～2029年、2034年
• 世界のニューポジェン（フィルグラスチム）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のニューポジェン（フィルグラスチム）市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 生物製剤
• バイオシミラー
• 世界のニューポジェン（フィルグラスチム）市場：適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法誘発性好中球減少症
• 慢性好中球減少症
• その他
• 世界のニューポジェン（フィルグラスチム）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のニューポジェン（フィルグラスチム）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のニューポジェン（フィルグラスチム）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• ニューポジェン（フィルグラスチム）市場：競合情勢
• ニューポジェン（フィルグラスチム）市場：企業プロファイル
  • Amgen Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• ニューポジェン（フィルグラスチム）市場、2029年：新たな機会を提供する国
• ニューポジェン（フィルグラスチム）市場、2029年：新たな機会を提供するセグメント
• ニューポジェン（フィルグラスチム）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that promotes the production of white blood cells in the bone marrow. It is used to prevent infections in patients with neutropenia resulting from chemotherapy, bone marrow transplantation, or specific medical conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug types of neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are sourced from living organisms and require complex manufacturing processes to achieve targeted therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and other conditions. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides neupogen (filgrastim) market statistics, including neupogen (filgrastim) industry global market size, regional shares, competitors with a neupogen (filgrastim) market share, detailed neupogen (filgrastim) market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. This neupogen (filgrastim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1,727.1 million in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to rising demand for cost-effective neutropenia treatment, expansion of healthcare access in emerging markets, increased government support for biosimilar penetration, improved focus on personalized medicine, and a growing elderly population. Major trends in the forecast period include increasing research and development investments in biosimilars, advancements in drug delivery systems for neutropenia treatments, rising partnerships for oncology drug commercialization, a stronger focus on patient affordability programs, and the development of next-generation G-CSF products.

The increasing prevalence of various diseases is expected to drive the growth of the neupogen (filgrastim) market in the coming years. Diseases, whether caused by infections, genetic factors, environmental influences, or lifestyle choices, have become more prevalent due to factors such as aging populations, sedentary lifestyles, pollution, and poor dietary habits. Neupogen (filgrastim) plays a crucial role in managing chemotherapy-induced neutropenia by stimulating the production of neutrophils, which helps enhance the immune system's ability to combat infections in patients with weakened immunity. This is essential in reducing hospitalizations and allowing continuous cancer treatments. According to Allergy UK, over 21 million people in the UK suffered from allergies in 2022, a number expected to rise, and nearly 3.5 million people in the UK are projected to live with cancer by 2025, highlighting the growing need for treatments like neupogen. These trends will significantly drive demand for neupogen (filgrastim) in the future.

Government initiatives for research and development in healthcare are expected to propel the neupogen (filgrastim) market. Governments worldwide are increasingly focusing on funding healthcare research and expanding life sciences manufacturing to improve the availability of medical treatments. For example, in 2022, the UK government announced £260 million in funding to support NHS-led research into new diagnostics and treatments and to expand life sciences manufacturing. Such investments foster innovation and provide greater access to advanced therapies, which directly supports the growth of treatments like neupogen.

A key trend in the neupogen (filgrastim) market is the development of biosimilars, which offer cost-effective alternatives to the original drug while maintaining similar safety, efficacy, and structural characteristics. Filgrastim biosimilars are designed to mimic Neupogen, stimulating neutrophil production to treat chemotherapy-induced neutropenia. A notable development in this area occurred in November 2022, when Amneal Pharmaceuticals and Kashiv Biosciences launched Releuko (filgrastim-ayow), a biosimilar to Neupogen, in the U.S. Releuko provides both intravenous and subcutaneous formulations, offering flexibility in dosing and improving accessibility to essential treatments. This trend of biosimilars is increasing the affordability and availability of chemotherapy support medications, driving further growth in the Neupogen market.

The Key player operating in the neupogen (filgrastim) market is Amgen Inc.

North America was the largest region in the neupogen (filgrastim) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neupogen (filgrastim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neupogen (filgrastim) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neupogen (filgrastim) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neupogen (filgrastim) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neupogen (filgrastim) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neupogen (filgrastim) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Biologic; Biosimilar
• 2) By Indication: Chemotherapy Induced Neutropenia; Chronic Neutropenia; Others
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neupogen (filgrastim) Market Characteristics

3. Neupogen (filgrastim) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Neupogen (filgrastim) Market Trends And Strategies

5. Neupogen (filgrastim) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Neupogen (filgrastim) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Neupogen (filgrastim) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Neupogen (filgrastim) Market Growth Rate Analysis
• 6.4. Global Neupogen (filgrastim) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Neupogen (filgrastim) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Neupogen (filgrastim) Total Addressable Market (TAM)

7. Global Neupogen (filgrastim) Market Pricing Analysis & Forecasts

8. Neupogen (filgrastim) Market Segmentation

• 8.1. Global Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologic
• Biosimilar
• 8.2. Global Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Induced Neutropenia
• Chronic Neutropenia
• Others
• 8.3. Global Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Neupogen (filgrastim) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Neupogen (filgrastim) Market Regional And Country Analysis

• 10.1. Global Neupogen (filgrastim) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Neupogen (filgrastim) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Neupogen (filgrastim) Market

• 11.1. Asia-Pacific Neupogen (filgrastim) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Neupogen (filgrastim) Market

• 12.1. China Neupogen (filgrastim) Market Overview
• 12.2. China Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Neupogen (filgrastim) Market

• 13.1. India Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Neupogen (filgrastim) Market

• 14.1. Japan Neupogen (filgrastim) Market Overview
• 14.2. Japan Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Neupogen (filgrastim) Market

• 15.1. Australia Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Neupogen (filgrastim) Market

• 16.1. South Korea Neupogen (filgrastim) Market Overview
• 16.2. South Korea Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Neupogen (filgrastim) Market

• 17.1. Western Europe Neupogen (filgrastim) Market Overview
• 17.2. Western Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Neupogen (filgrastim) Market

• 18.1. UK Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Neupogen (filgrastim) Market

• 19.1. Germany Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Neupogen (filgrastim) Market

• 20.1. France Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neupogen (filgrastim) Market

• 21.1. Eastern Europe Neupogen (filgrastim) Market Overview
• 21.2. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Neupogen (filgrastim) Market

• 22.1. North America Neupogen (filgrastim) Market Overview
• 22.2. North America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Neupogen (filgrastim) Market

• 23.1. USA Neupogen (filgrastim) Market Overview
• 23.2. USA Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Neupogen (filgrastim) Market

• 24.1. Canada Neupogen (filgrastim) Market Overview
• 24.2. Canada Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Neupogen (filgrastim) Market

• 25.1. South America Neupogen (filgrastim) Market Overview
• 25.2. South America Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Neupogen (filgrastim) Market

• 26.1. Middle East Neupogen (filgrastim) Market Overview
• 26.2. Middle East Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Neupogen (filgrastim) Market

• 27.1. Africa Neupogen (filgrastim) Market Overview
• 27.2. Africa Neupogen (filgrastim) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Neupogen (filgrastim) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Neupogen (filgrastim) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Neupogen (filgrastim) Market Competitive Landscape And Company Profiles

• 28.1. Neupogen (filgrastim) Market Competitive Landscape
• 28.2. Neupogen (filgrastim) Market Company Profiles
  • 28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Neupogen (filgrastim) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Neupogen (filgrastim) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Neupogen (filgrastim) Market

32. Recent Developments In The Neupogen (filgrastim) Market

33. Neupogen (filgrastim) Market High Potential Countries, Segments and Strategies

• 33.1 Neupogen (filgrastim) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Neupogen (filgrastim) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Neupogen (filgrastim) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer